As per MRFR analysis, the Peptide and Oligonucleotide CDMO Market Size was estimated at 5.82 (USD Billion) in 2022.
The Peptide and Oligonucleotide CDMO Market Industry is expected to grow from 6.74(USD Billion) in 2023 to 25.25 (USD Billion) by 2032. The Peptide and Oligonucleotide CDMO Market CAGR (growth rate) is expected to be around 15.8% during the forecast period (2024 - 2032).
The Peptide and Oligonucleotide CDMO Market stands to benefit as pharmaceutical and biotechnology markets continue to grow. There is an increasing trend among pharmaceutical companies to depend on CDMOs in order to cut costs, speed up drug development, and make use of the CDMO's skillset. This market is also fuelled by the increasing number of chronic diseases and the advent of personalized medicine, which in turn creates the need for complex peptides and oligonucleotides.
One of the market advancements is the utilization of enhanced technologies such as gene editing and RNA interference that make drug development faster and even more efficient. At this time, the market is gaining momentum towards cost-cutting and efficiency in the manufacturing processes, which boosts the use of continuous manufacturing and automation. Apart from this, the peaking demand for biologics and varying biosimilars also add to the growth of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The growing prevalence of chronic diseases and the increasing demand for personalized medicine are key factors driving the growth of the Peptide and Oligonucleotide CDMO Market Industry. Gene and cell therapies hold immense promise for treating a wide range of diseases, including cancer, genetic disorders, and neurodegenerative diseases. Peptides and oligonucleotides play a crucial role in these therapies, serving as building blocks for gene editing tools, targeted drug delivery systems, and immunotherapies.The advancements in gene and cell therapies have created a surge in demand for Peptide And Oligonucleotide Cdmo services as companies seek specialized expertise and infrastructure to develop and manufacture these complex therapies. The increasing number of clinical trials and regulatory approvals for gene and cell therapies is expected to further fuel the growth of the Peptide and Oligonucleotide CDMO Market Industry in the coming years.
The Peptide and Oligonucleotide CDMO Market Industry is witnessing rapid technological advancements that are transforming the manufacturing processes of peptides and oligonucleotides. Automation, artificial intelligence (AI), and machine learning (ML) are being increasingly adopted by Cdmo providers to streamline operations, improve efficiency, and reduce manufacturing costs. These technologies enable real-time monitoring and control of manufacturing processes, reducing the risk of errors and ensuring consistent product quality.Additionally, the use of advanced analytical techniques and high-throughput screening platforms accelerates the development and characterization of peptides and oligonucleotides, further contributing to cost reduction and faster time-to-market.
The pharmaceutical industry is witnessing a shift towards biologics and biosimilars, driven by their efficacy and specificity in treating complex diseases. Peptides and oligonucleotides are essential components of many biologics and biosimilars, and the growing demand for these therapies is creating significant opportunities for the Peptide and Oligonucleotide CDMO Market Industry. Cdmo providers are expanding their capabilities to cater to the unique requirements of biologics and biosimilars manufacturing, including specialized expertise in cell culture, fermentation, and purification processes.The increasing number of biosimilar approvals and the growing adoption of biologics in emerging markets are expected to drive the demand for Peptide And Oligonucleotide Cdmo services in the coming years.
The Peptide and Oligonucleotide CDMO Market is segmented by Type into Peptides, Oligonucleotides, and Conjugates. Peptides are a type of biomolecule composed of two or more amino acids linked by peptide bonds. They are essential components of cells and play a crucial role in various biological processes, such as hormone regulation, immune response, and cell signaling. In the Peptide and Oligonucleotide CDMO Market, peptides are primarily used for therapeutic purposes, particularly in the development of drugs for treating chronic diseases such as cancer and diabetes.The global peptide market is projected to reach USD 24.3 billion by 2024, exhibiting a CAGR of 8.5% during the forecast period (2023-2024). Oligonucleotides are short, single-stranded DNA or RNA molecules. They are used in various applications, including gene therapy, diagnostics, and drug development. In the Peptide and Oligonucleotide CDMO Market, oligonucleotides are primarily used for antisense therapy, which involves targeting specific genes to inhibit their expression. The global oligonucleotide market is expected to grow significantly in the coming years, driven by the increasing demand for personalized medicine and the development of new therapeutic modalities.Conjugates are molecules that combine peptides or oligonucleotides with other molecules, such as proteins or antibodies. They are designed to improve the stability, delivery, and efficacy of therapeutic agents. In the Peptide and Oligonucleotide CDMO Market, conjugates are gaining increasing attention as they offer the potential to overcome the challenges associated with traditional drug delivery approaches. The global conjugate market is anticipated to witness substantial growth in the future, driven by the development of novel drug delivery technologies and the increasing prevalence of chronic diseases.Overall, the Type segment of the Peptide and Oligonucleotide CDMO Market is highly dynamic and evolving. The increasing demand for personalized medicine, the development of new therapeutic modalities, and the technological advancements in drug delivery are driving the growth of this market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Peptide and Oligonucleotide CDMO Market is segmented by application into Pharmaceuticals, Diagnostics, and Cosmetics. The Pharmaceuticals segment held the largest market share in 2023, owing to the increasing demand for peptide and oligonucleotide-based therapeutics for the treatment of various diseases such as cancer, diabetes, and autoimmune disorders. The Diagnostics segment is expected to grow at a significant CAGR during the forecast period, driven by the rising demand for personalized medicine and the development of new diagnostic technologies.The Cosmetics segment is expected to witness steady growth, driven by the increasing use of peptides and oligonucleotides in anti-aging and skin care products.
Synthesis Route segments the Peptide and Oligonucleotide CDMO Market into Solid-phase Synthesis, Solution-phase Synthesis, and Automated Synthesis. Among these, Solid-phase Synthesis held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period. This is attributed to the increased adoption of solid-phase synthesis due to its advantages, such as higher yields, purity, and scalability. Solution-phase Synthesis is expected to witness the fastest growth rate during the forecast period due to its simplicity and cost-effectiveness.Automated Synthesis is gaining popularity due to its ability to reduce labor costs and improve efficiency.
The Peptide and Oligonucleotide CDMO Market is segmented by scale into preclinical, clinical, and commercial. The clinical segment held the market share in 2023, owing to the increasing number of clinical trials for new drugs and therapies. The preclinical segment is expected to grow at the highest CAGR during the forecast period due to the rising demand for preclinical studies to assess the safety and efficacy of new drug candidates. The commercial segment is expected to account for a significant share of the market in 2032 as more drugs and therapies are approved for commercial use.
The Peptide and Oligonucleotide CDMO Market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest regional segment, accounting for over 40% of the global market in 2023. Europe is the second largest regional segment, followed by APAC. The APAC region is expected to grow at the highest CAGR during the forecast period, due to the increasing demand for peptides and oligonucleotides in the region. The growth of the Peptide and Oligonucleotide CDMO Market is driven by several factors, including the increasing demand for peptides and oligonucleotides in the pharmaceutical and biotechnology industries, the rising prevalence of chronic diseases, and the growing adoption of personalized medicine.The market is also expected to benefit from the increasing number of government initiatives to support the development of new peptide and oligonucleotide-based therapies. The Peptide and Oligonucleotide CDMO Market is highly competitive, with a number of major players operating in the market. These players include Thermo Fisher Scientific, Lonza, Bachem, and PeptiDream. The market is also characterized by a number of emerging players, who are offering innovative peptide and oligonucleotide-based products and services.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Major players in the Peptide and Oligonucleotide CDMO Market industry are focusing on expanding their product portfolio and geographical reach. They are also investing in research and development to develop new and innovative products. Leading Peptide and Oligonucleotide CDMO Market players are adopting various strategies such as mergers and acquisitions, partnerships, and collaborations to gain a competitive edge in the market. The Peptide and Oligonucleotide CDMO Market development is driven by factors such as increasing demand for peptide and oligonucleotide therapies, growing prevalence of chronic diseases, and technological advancements. The competitive landscape of the Peptide and Oligonucleotide CDMO Market is characterized by the presence of both established and emerging players.A leading company in the Peptide and Oligonucleotide CDMO Market is Thermo Fisher Scientific. The company offers a wide range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. Thermo Fisher Scientific has a global presence and a strong customer base. The company is focused on providing high-quality products and services to its customers. Thermo Fisher Scientific is also investing in research and development to develop new and innovative products.A competitor company in the Peptide and Oligonucleotide CDMO Market is GeneCust. The company offers a range of peptide and oligonucleotide synthesis services, as well as analytical and purification services. GeneCust has a strong presence in the Asia-Pacific region and is expanding its global reach. The company is focused on providing cost-effective products and services to its customers. GeneCust is also investing in research and development to develop new and innovative products.
The Peptide and Oligonucleotide CDMO Market is projected to reach USD 25.25 billion by 2032, exhibiting a CAGR of 15.8% during the forecast period. Key factors driving market growth include increasing demand for personalized medicine, rising prevalence of chronic diseases, and advancements in gene editing technologies.Recent news developments include: In 2023, Thermo Fisher Scientific acquired PeproTech, a leading manufacturer of peptides and proteins, to strengthen its position in the CDMO market. In 2024, Lonza announced plans to invest CHF 1 billion in its Visp, Switzerland site to expand its CDMO capabilities for peptides and oligonucleotides. In 2025, Catalent acquired Paragon Bioservices, a provider of gene therapy and viral vector CDMO services, to enhance its offerings in the growing gene therapy market.These developments underscore the increasing demand for CDMO services in the peptide and oligonucleotide market, driven by the growing complexity and scale of drug development projects.
| Report Attribute/Metric | Details |
| Market Size 2022 | 5.82(USD Billion) |
| Market Size 2023 | 6.74(USD Billion) |
| Market Size 2032 | 25.25(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 15.8% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2022 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Jubilant Holdist, Peptide International, CordenPharma International, Peptech, GenScript Biotech, Thermo Fisher Scientific, Catalent, BioSynthesis, Lonza Group, Auspeptides, Piramal Enterprises, Synpeptide Technologies, PolyPeptide Laboratories, Bachem Group, Wuxi AppTec |
| Segments Covered | Type, Application, Synthesis Route, Scale, Regional |
| Key Market Opportunities | Increased demand for personalized medicine Growing adoption of oligonucleotide therapeutics Advancements in gene editing technologies Expansion of peptide-based drug development Rising prevalence of chronic diseases. |
| Key Market Dynamics | Growing demand technological advancements increasing RampD investments strategic partnerships expanding applications |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Peptide and Oligonucleotide CDMO Market is projected to Register a CAGR of 15.8% from 2024 to 2032.
The Peptide and Oligonucleotide CDMO Market is expected to reach a valuation of 25.25 Billion USD by 2032.
North America is expected to hold the largest market share in the Peptide and Oligonucleotide CDMO Market.
Key applications of Peptide And Oligonucleotide Cdmo include drug discovery, diagnostics, and therapeutics.
Key competitors in the Peptide and Oligonucleotide CDMO Market include Thermo Fisher Scientific, Lonza, and Bachem.
Major factors driving the growth of the Peptide and Oligonucleotide CDMO Market include increasing demand for personalized medicine and growing investment in biotechnology research.
Challenges faced by the Peptide and Oligonucleotide CDMO Market include stringent regulatory requirements and high production costs.
Opportunities for growth in the Peptide and Oligonucleotide CDMO Market include technological advancements and increasing demand for outsourcing.
Key trends in the Peptide and Oligonucleotide CDMO Market include automation and miniaturization of manufacturing processes.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
